Evidence map›Paper›PMID 38962624›Full record

ArticleCureus2024

Promising Results of an Exclusive Radiotherapy Treatment of an Inoperable Giant Eyelid Sebaceous Carcinoma.

Asmae Hamdan, Salma El Baz, Hanan El Kacemi, Tayeb Kebdani, Khalid Hassouni

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Asmae HamdanDepartment of Radiotherapy, National Institute of Oncology, Mohammed V University, Faculty of Medicine, Rabat, MAR.
Salma El BazDepartment of Radiotherapy, National Institute of Oncology, Mohammed V University, Faculty of Medicine, Rabat, MAR.
Hanan El KacemiDepartment of Radiotherapy, National Institute of Oncology, Mohammed V University, Faculty of Medicine, Rabat, MAR.
Tayeb KebdaniDepartment of Radiotherapy, National Institute of Oncology, Mohammed V University, Faculty of Medicine, Rabat, MAR.
Khalid HassouniDepartment of Radiotherapy, National Institute of Oncology, Mohammed V University, Faculty of Medicine, Rabat, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eyelid sebaceous carcinoma is a rare malignant tumor. Surgical excision is generally the standard curative treatment. However, in cases where surgery is not possible due to locally advanced tumors, definitive radiotherapy can be considered an option. A 71-year-old man presented with a history of eyelid sebaceous carcinoma dating back two years. The tumor, measuring 93 x 55 x 56 mm and located on the right upper eyelid, was not surgically resected. He was then treated with intensity-modulated radiotherapy, receiving a total dose of 70 Gy in 35 fractions. After 24 months, the patient shows no local recurrence.

Indexed as

case reportexclusive radiotherapygiantinoperablesebaceous carcinoma

Identifiers

PMID38962624
PMCPMC11221620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.